1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 73, 2022
  5. Article

Annual Review of Medicine

Volume 73, 2022

Clinical Perspectives on IgG4-Related Disease and Its Classification

Abstract

Immunoglobulin G4–related disease (IgG4-RD) is a systemic immune-mediated fibroinflammatory disease. Since its discovery nearly two decades ago, our understanding of its pathophysiology and clinical manifestations has grown substantially. Early diagnosis and treatment of this elusive disease can prevent substantial organ damage from end-stage fibrosis, emphasizing the need for prompt recognition and accurate characterization of IgG4-RD. The classification criteria endorsed by the American College of Rheumatology and the European Alliance of Associations for Rheumatology in 2019 provide a framework for establishing the diagnosis in the clinical setting. This process involves recognizing the typical manifestations of the disease and incorporating clinical, radiological, serological, and histopathological information as well as excluding disease mimickers. Glucocorticoids and rituximab are effective at inducing remission in IgG4-RD in most patients, but the optimal approach to long-term management of IgG4-RD remains an area of active clinical research.

Keyword(s): autoimmune pancreatitis, classification criteria, immunoglobulin G4–related disease, Mikulicz disease, retroperitoneal fibrosis, Riedel thyroiditis
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-050219-034449
2022-01-27
2024-05-05
Loading full text...

Full text loading...

/deliver/fulltext/med/73/1/annurev-med-050219-034449.html?itemId=/content/journals/10.1146/annurev-med-050219-034449&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Kamisawa T, Funata N, Hayashi Y et al. 2003. A new clinicopathological entity of IgG4-related autoimmune disease. J. Gastroenterol. 38:10982–84
     [Google Scholar]
  2. 2. 
    Yamamoto M, Takahashi H, Ohara M et al. 2006. A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod. Rheumatol. 16:6335–40
     [Google Scholar]
  3. 3. 
    Dahlgren M, Khosroshahi A, Nielsen GP et al. 2010. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res 62:91312–18
     [Google Scholar]
  4. 4. 
    Inoue D, Yoshida K, Yoneda N et al. 2015. IgG4-related disease: dataset of 235 consecutive patients. Medicine 94:15e680
     [Google Scholar]
  5. 5. 
    Wallace ZS, Deshpande V, Mattoo H et al. 2015. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 67:92466–75
     [Google Scholar]
  6. 6. 
    Karim F, Loeffen J, Bramer W et al. 2016. IgG4-related disease: a systematic review of this unrecognized disease in pediatrics. Pediatr. Rheumatol. Online J. 14:118
     [Google Scholar]
  7. 7. 
    Wallwork R, Perugino CA, Fu X et al. 2021. The association of smoking with immunoglobulin G4–related disease: a case–control study. Rheumatology 60:530–17
     [Google Scholar]
  8. 8. 
    de Buy Wenniger LJM, Culver EL, Beuers U. 2014. Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology 60:41453–54
     [Google Scholar]
  9. 9. 
    Doorenspleet ME, Hubers LM, Culver EL et al. 2016. Immunoglobulin G4+ B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. Hepatology 64:2501–7
     [Google Scholar]
  10. 10. 
    Wallace ZS, Wallace CJ, Lu N et al. 2016. Association of IgG4-related disease with history of malignancy. Arthritis Rheumatol 68:92283–89
     [Google Scholar]
  11. 11. 
    Perugino CA, Stone JH. 2020. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat. Rev. Rheumatol. 16:12702–14
     [Google Scholar]
  12. 12. 
    Wallace ZS, Mattoo H, Carruthers M et al. 2015. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann. Rheum. Dis. 74:1190–95
     [Google Scholar]
  13. 13. 
    Mattoo H, Mahajan VS, Della Torre E et al. 2014. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J. Allergy Clin. Immunol. 134:3679–87
     [Google Scholar]
  14. 14. 
    Akiyama M, Suzuki K, Yamaoka K et al. 2015. Number of circulating follicular helper 2 T cells correlates with IgG4 and interleukin-4 levels and plasmablast numbers in IgG4-related disease. Arthritis Rheumatol 67:92476–81
     [Google Scholar]
  15. 15. 
    Maehara T, Mattoo H, Mahajan VS et al. 2018. The expansion in lymphoid organs of IL-4+ BATF+ T follicular helper cells is linked to IgG4 class switching in vivo. Life Sci. Alliance 1:1e201800050
     [Google Scholar]
  16. 16. 
    Ito F, Kamekura R, Yamamoto M et al. 2019. IL-10+ T follicular regulatory cells are associated with the pathogenesis of IgG4-related disease. Immunol. Lett. 207:56–63
     [Google Scholar]
  17. 17. 
    Mattoo H, Mahajan VS, Maehara T et al. 2016. Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. J. Allergy Clin. Immunol. 138:3825–38
     [Google Scholar]
  18. 18. 
    Perugino CA, AlSalem SB, Mattoo H et al. 2019. Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. J. Allergy Clin. Immunol. 143:2736–45.e6
     [Google Scholar]
  19. 19. 
    Du H, Shi L, Chen P et al. 2015. Prohibitin is involved in patients with IgG4 related disease. PLOS ONE 10:5e0125331
     [Google Scholar]
  20. 20. 
    Lin W, Zhang P, Chen H et al. 2017. Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease. Arthritis Res. Ther. 19:125
     [Google Scholar]
  21. 21. 
    Deshpande V, Zen Y, Chan JK et al. 2012. Consensus statement on the pathology of IgG4-related disease. Mod. Pathol. 25:91181–92
     [Google Scholar]
  22. 22. 
    Maehara T, Mattoo H, Ohta M et al. 2017. Lesional CD4+ IFN-γ+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Ann. Rheum. Dis. 76:2377–85
     [Google Scholar]
  23. 23. 
    Kubo S, Nakayamada S, Zhao J et al. 2018. Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease. Rheumatology 57:3514–24
     [Google Scholar]
  24. 24. 
    Shiokawa M, Kodama Y, Kuriyama K et al. 2016. Pathogenicity of IgG in patients with IgG4-related disease. Gut 65:81322–32
     [Google Scholar]
  25. 25. 
    Trampert DC, Hubers LM, van de Graaf SFJ et al. 2018. On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease. Biochim. Biophys. Acta Mol. Basis Dis. 1864:4 Part B1401–9
     [Google Scholar]
  26. 26. 
    Wallace ZS, Naden RP, Chari S et al. 2020. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann. Rheum. Dis. 79:177–87
     [Google Scholar]
  27. 27. 
    Della Torre E, Mancuso G, Lanzillotta M et al. 2021. Urgent manifestations of immunoglobulin G4–related disease. Scand. J. Rheumatol. 50:148–51
     [Google Scholar]
  28. 28. 
    Saeki T, Kobayashi D, Ito T et al. 2018. Comparison of clinical and laboratory features of patients with and without allergic conditions in IgG4-related disease: a single-center experience in Japan. Mod. Rheumatol. 28:5845–48
     [Google Scholar]
  29. 29. 
    Culver EL, Sadler R, Bateman AC et al. 2017. Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease. Clin. Gastroenterol. Hepatol. 15:91444–52.e6
     [Google Scholar]
  30. 30. 
    Della Torre E, Germanò T, Ramirez GA et al. 2020. IgG4-related disease and allergen-specific immunotherapy. Ann. Allergy Asthma Immunol. 124:6631–33
     [Google Scholar]
  31. 31. 
    Della Torre E, Mattoo H, Mahajan VS et al. 2014. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy 69:2269–72
     [Google Scholar]
  32. 32. 
    Sanders S, Fu X, Zhang Y et al. 2020. Lifetime allergy symptoms in IgG4-related disease: a case-control study. Arthritis Care Res. In press. https://doi.org/10.1002/acr.24545
    [Crossref] [Google Scholar]
  33. 33. 
    Ueno M, Nakano K, Miyagawa I et al. 2020. Five cases of IgG4-related disease with nasal mucosa and sinus involvement. Intern. Med. 59:151905–11
     [Google Scholar]
  34. 34. 
    Pace C, Ward S 2010. A rare case of IgG4-related sclerosing disease of the maxillary sinus associated with bone destruction. J. Oral. Maxillofac. Surg. 68:102591–93
     [Google Scholar]
  35. 35. 
    Piao Y, Yu W, He C et al. 2016.. [ IgG4-related sialodacryoadenitis and chronic rhinosinusitis: a clinicopathologic analysis of 13 cases. .] Chin. J. Pathol. 45:3180–85 In Chinese )
     [Google Scholar]
  36. 36. 
    Karim AF, Verdijk RM, Nagtegaal AP et al. 2017. To distinguish IgG4-related disease from seronegative granulomatosis with polyangiitis. Rheumatology 56:122245–47
     [Google Scholar]
  37. 37. 
    Stan MN, Sonawane V, Sebo TJ et al. 2017. Riedel's thyroiditis association with IgG4-related disease. Clin. Endocrinol. 86:3425–30
     [Google Scholar]
  38. 38. 
    Takeshima K, Inaba H, Ariyasu H et al. 2015. Clinicopathological features of Riedel's thyroiditis associated with IgG4-related disease in Japan. Endocr. J. 62:8725–31
     [Google Scholar]
  39. 39. 
    Zala A, Berhane T, Juhlin CC et al. 2020. Riedel thyroiditis. J. Clin. Endocrinol. Metab. 105:9dgaa468
     [Google Scholar]
  40. 40. 
    Wallace ZS, Perugino C, Matza M et al. 2019. Immunoglobulin G4–related disease. Clin. Chest. Med. 40:3583–97
     [Google Scholar]
  41. 41. 
    Murata Y, Aoe K, Mimura Y 2019. Pleural effusion related to IgG4. Curr. Opin. Pulm. Med. 25:4384–90
     [Google Scholar]
  42. 42. 
    Sakata K, Kikuchi J, Emoto K et al. 2021. Refractory IgG4-related pleural disease with chylothorax: a case report and literature review. Intern. Med. 60:132135–43
     [Google Scholar]
  43. 43. 
    Kato E, Takayanagi N, Ishiguro T et al. 2014. IgG4-related pleuritis with chylothorax. Intern. Med. 53:141545–48
     [Google Scholar]
  44. 44. 
    Ansari-Gilani K, Gilkeson RC. 2020. Multimodality imaging of IgG4 related coronary artery aneurysm. Echocardiography 37:6979–81
     [Google Scholar]
  45. 45. 
    Matsuyama S, Kishigami T, Sakamoto M. 2020. A case of giant right coronary artery aneurysm due to IgG4-related disease. Gen. Thorac. Cardiovasc. Surg. 68:121453–56
     [Google Scholar]
  46. 46. 
    Ruggio A, Iaconelli A, Panaioli E et al. 2018. Coronary artery aneurysms presenting as acute coronary syndrome: an unusual case of IgG4-related disease vascular involvement. Can. J. Cardiol. 34:81088.e7–10
     [Google Scholar]
  47. 47. 
    Madhani K, Farrell JJ. 2018. Management of autoimmune pancreatitis. Gastrointest. Endosc. Clin. N. Am. 28:4493–519
     [Google Scholar]
  48. 48. 
    Sandrasegaran K, Menias CO. 2018. Imaging in autoimmune pancreatitis and immunoglobulin G4–related disease of the abdomen. Gastroenterol. Clin. N. Am. 47:3603–19
     [Google Scholar]
  49. 49. 
    Khandelwal A, Inoue D, Takahashi N. 2020. Autoimmune pancreatitis: an update. Abdom. Radiol. 45:51359–70
     [Google Scholar]
  50. 50. 
    Tanaka A. 2019. IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut Liver 13:3300–7
     [Google Scholar]
  51. 51. 
    Ali AH, Bi Y, Machicado JD et al. 2020. The long-term outcomes of patients with immunoglobulin G4–related sclerosing cholangitis: the Mayo Clinic experience. J. Gastroenterol. 55:111087–97
     [Google Scholar]
  52. 52. 
    Pradhan D, Pattnaik N, Silowash R et al. 2015. IgG4-related kidney disease—a review. Pathol. Res. Pract. 211:10707–11
     [Google Scholar]
  53. 53. 
    Teng F, Lu H, Zheng K et al. 2020. Urinary system manifestation of IgG4-related disease: clinical, laboratory, radiological, and pathological spectra of a Chinese single-centre study. J. Immunol. Res. 2020:5851842
     [Google Scholar]
  54. 54. 
    Khosroshahi A, Carruthers MN, Stone JH et al. 2013. Rethinking Ormond's disease: “idiopathic” retroperitoneal fibrosis in the era of IgG4-related disease. Medicine 92:282–91
     [Google Scholar]
  55. 55. 
    Koo BS, Koh YW, Hong S et al. 2015. Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis. Mod. Rheumatol. 25:2194–98
     [Google Scholar]
  56. 56. 
    Liu Y, Zhu L, Wang Z et al. 2021. Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study. Rheumatology 60:2767–72
     [Google Scholar]
  57. 57. 
    AbdelRazek MA, Venna N, Stone JH. 2018. IgG4-related disease of the central and peripheral nervous systems. Lancet Neurol 17:2183–92
     [Google Scholar]
  58. 58. 
    Soussan JB, Deschamps R, Sadik JC et al. 2017. Infraorbital nerve involvement on magnetic resonance imaging in European patients with IgG4-related ophthalmic disease: a specific sign. Eur. Radiol. 27:41335–43
     [Google Scholar]
  59. 59. 
    Chwalisz BK, Stone JH. 2018. Neuro-ophthalmic complications of IgG4-related disease. Curr. Opin. Ophthalmol. 29:6485–94
     [Google Scholar]
  60. 60. 
    Carruthers MN, Khosroshahi A, Augustin T et al. 2015. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann. Rheum. Dis. 74:114–18
     [Google Scholar]
  61. 61. 
    Culver EL, Sadler R, Simpson D et al. 2016. Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am. J. Gastroenterol. 111:5733–43
     [Google Scholar]
  62. 62. 
    Carruthers MN, Topazian MD, Khosroshahi A et al. 2015. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann. Rheum. Dis. 74:61171–77
     [Google Scholar]
  63. 63. 
    Wallace ZS, Mattoo H, Mahajan VS et al. 2016. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology 55:61000–8
     [Google Scholar]
  64. 64. 
    Sasaki T, Akiyama M, Kaneko Y et al. 2018. Risk factors of relapse following glucocorticoid tapering in IgG4-related disease. Clin. Exp. Rheumatol. 112:3186–89
     [Google Scholar]
  65. 65. 
    Zhao EJ, Carruthers MN, Li CH et al. 2020. Conditions associated with polyclonal hypergammaglobulinemia in the IgG4-related disease era: a retrospective study from a hematology tertiary care center. Haematologica 105:3e121–23
     [Google Scholar]
  66. 66. 
    Zhang X, Zhang P, Li J et al. 2019. Different clinical patterns of IgG4-RD patients with and without eosinophilia. Sci. Rep. 9:16483
     [Google Scholar]
  67. 67. 
    Martín-Nares E, Hernandez-Molina G, Rodríguez-Ramírez S et al. 2020. IgG4-related kidney disease: experience from a Mexican cohort. Clin. Rheumatol. 39:113401–8
     [Google Scholar]
  68. 68. 
    Zhou J, Peng Y, Peng L et al. 2020. Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study. Arthritis Res. Ther. 22:1255
     [Google Scholar]
  69. 69. 
    Kawano M, Saeki T, Nakashima H et al. 2011. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin. Exp. Nephrol. 15:5615–26
     [Google Scholar]
  70. 70. 
    Tang J, Cai S, Ye C et al. 2020. Biomarkers in IgG4-related disease: a systematic review. Semin. Arthritis Rheum. 50:2354–59
     [Google Scholar]
  71. 71. 
    Girish BN, Rajesh G, Vaidyanathan K et al. 2009. Zinc status in chronic pancreatitis and its relationship with exocrine and endocrine insufficiency. J. Pancreas 10:6651–56
     [Google Scholar]
  72. 72. 
    Jøker-Jensen H, Mathiasen AS, Køhler M et al. 2020. Micronutrient deficits in patients with chronic pancreatitis: prevalence, risk factors and pitfalls. Eur. J. Gastroenterol. Hepatol. 32:101328–34
     [Google Scholar]
  73. 73. 
    Vaona B, Stanzial AM, Talamini G et al. 2005. Serum selenium concentrations in chronic pancreatitis and controls. Dig. Liver Dis. 37:7522–25
     [Google Scholar]
  74. 74. 
    Rasmussen HH, Irtun O, Olesen SS et al. 2013. Nutrition in chronic pancreatitis. World J. Gastroenterol. 19:427267–75
     [Google Scholar]
  75. 75. 
    Zhang W, Stone JH. 2019. Management of IgG4-related disease. Lancet Rheumatol 1:1e55–65
     [Google Scholar]
  76. 76. 
    Wallace ZS, Zhang Y, Perugino CA et al. 2019. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann. Rheum. Dis. 78:3406–12
     [Google Scholar]
  77. 77. 
    Lanzillotta M, Campochiaro C, Mancuso G et al. 2020. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology 59:92435–42
     [Google Scholar]
  78. 78. 
    Masaki Y, Matsui S, Saeki T et al. 2017. A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. Mod. Rheumatol. 27:5849–54
     [Google Scholar]
  79. 79. 
    Wu Q, Chang J, Chen H et al. 2017. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial. Int. J. Rheum. Dis. 20:5639–46
     [Google Scholar]
  80. 80. 
    Ebbo M, Grados A, Samson M et al. 2017. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLOS ONE 12:9e0183844
     [Google Scholar]
  81. 81. 
    Campochiaro C, Della Torre E, Lanzillotta M et al. 2020. Long-term efficacy of maintenance therapy with rituximab for IgG4-related disease. Eur. J. Intern. Med. 74:92–98
     [Google Scholar]
  82. 82. 
    Khosroshahi A, Carruthers MN, Deshpande V et al. 2012. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine 91:157–66
     [Google Scholar]
  83. 83. 
    Boyeva V, Alabsi H, Seidman MA et al. 2020. Use of rituximab in idiopathic retroperitoneal fibrosis. BMC Rheumatol 4:40
     [Google Scholar]
  84. 84. 
    Lanzillotta M, Fernàndez-Codina A, Culver E et al. 2021. Emerging therapy options for IgG4-related disease. Expert Rev. Clin. Immunol. 17:5471–83
     [Google Scholar]
  85. 85. 
    Yunyun F, Yu P, Panpan Z et al. 2019. Efficacy and safety of low dose mycophenolate mofetil treatment for immunoglobulin G4–related disease: a randomized clinical trial. Rheumatology 58:152–60
     [Google Scholar]
  86. 86. 
    Yunyun F, Yu C, Panpan Z et al. 2017. Efficacy of cyclophosphamide treatment for immunoglobulin G4–related disease with addition of glucocorticoids. Sci. Rep. 7:6195
     [Google Scholar]
/content/journals/10.1146/annurev-med-050219-034449
Loading
Clinical Perspectives on IgG4-Related Disease and Its Classification
Annual Review of Medicine 73, 545 (2022); https://doi.org/10.1146/annurev-med-050219-034449
/content/journals/10.1146/annurev-med-050219-034449
/content/journals/10.1146/annurev-med-050219-034449
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error